Depression, Stress, May Drive Breast Cancer Survivor Fatigue

Long-term fatigue is among the most common and debilitating side effects of breast cancer therapy, potentially severely impacting a survivor’s quality of life. For years, clinicians and researchers hypothesized that this persistent exhaustion resulted from chemotherapy-induced cardiotoxicity, which causes subtle, long-term damage to cardiovascular function. However, findings from the prospective, multicenter cohort study known as the Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT) trial (NCT02791581) are challenging these assumptions.

In a newly published analysis in JAMA Network Open, researchers revealed that psychological factors—specifically depression and stress—are more closely linked to long-term fatigue in breast cancer survivors than objective changes in cardiovascular function. This paradigm-shifting insight, combined with a related UPBEAT analysis in Supportive Care in Cancer investigating different chemotherapy regimens, provides oncology nurses with an evidence-based framework to screen, counsel, and support patients.

Chemotherapy Type Does Not Dictate Fatigue Trajectories

To compare how different treatments impact symptoms, investigators analyzed a subset of 284 participants from the UPBEAT study (WF-97415). The analysis compared patients receiving cardiotoxic, anthracycline-based chemotherapy (all receiving doxorubicin), patients receiving non-anthracycline chemotherapy, patients taking aromatase inhibitors (AIs) without chemotherapy, and female controls without cancer.

Historically, clinicians assumed that aggressive anthracycline-based chemotherapy caused more persistent fatigue than less toxic regimens. However, the UPBEAT study suggested otherwise:

• Identical Trajectories: Both cohorts experienced a sharp increase in fatigue at 3 months, followed by a partial recovery at 12 months [2].
• No Statistically Significant Difference: There was no meaningful difference in Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue scores between the groups at any evaluated time point.
• Resilience in Endocrine-Only Therapy: Patients receiving AIs alone maintained stable fatigue levels that did not significantly differ from the healthy controls, suggesting these agents do not inherently drive severe fatigue.

The Psychological Link to Long-Term Survivorship Fatigue

While chemotherapy-induced fatigue peaked during active treatment and partially resolved by one year, a separate, longer-term UPBEAT analysis followed 381 participants—including 236 women with stage I to III breast cancer and 145 non-cancer controls—for 24 months. More than a third of patients receiving chemotherapy experienced a meaningful worsening of fatigue compared with baseline. These long-term fatigue outcomes were not associated with objective cardiovascular measures—including six-minute walk distance, left ventricular ejection fraction, or cardiac output. Instead, they were heavily predicted by baseline levels of stress and depressive symptoms.

"This research is remarkable because it challenges our assumptions about what actually drives fatigue in breast cancer survivors," noted W. Gregory Hundley, M.D., the study’s senior author and director of the VCU Health Pauley Heart Center. "As a cardiologist, my instinct is always to look first at the heart. What this study tells us is that, in this case, the answer can lie elsewhere."

Key Takeaways for Oncology Nursing Practice

Oncology nurses are uniquely positioned to translate these findings into daily clinical workflows to improve cancer survivor outcomes:

• Implement Early and Regular Screenings: Oncology nurses must routinely screen for both fatigue and mental health distress (depression and stress) at baseline, during active chemotherapy, and throughout the survivorship period.
• Disrupt the Cardiotoxicity Assumption: When a survivor presents with chronic fatigue, care teams should not assume it is driven solely by cardiac decline. While cardiac monitoring remains vital, nurses must advocate for concurrent psychosocial evaluations.
• Employ Early Multimodal Interventions: Nurses should proactively recommend and coordinate evidence-based interventions recommended by ASCO to mitigate fatigue. These include structured physical activity, cognitive-behavioral therapy, and mind-body interventions like mindfulness or yoga.
• Provide Reassuring Patient Education: Nurses can counsel patients starting chemotherapy that while temporary, severe fatigue is common and peaks around three months, they can expect a significant, partial recovery by one year regardless of chemotherapy type.

These findings highlight the complex, multisystem nature of cancer-related fatigue, underscoring that physical symptoms are often deeply intertwined with psychological well-being. By integrating comprehensive mental health screenings alongside traditional cardiac monitoring, oncology nursing teams can deliver holistic, personalized care.

References

1. New research finds depression and stress — not just heart function — drive long-term fatigue for breast cancer survivors. VCU Health News. August 20, 2026. Accessed August 31, 2026. https://www.vcuhealth.org/news/new-research-finds-depression-and-stress--not-just-heart-function--drive-long-term-fatigue-for-breast-cancer-survivors
2. Avis NE, Levine BJ, Klepin HD, et al. The impact of non- and anthracycline-based chemotherapy on fatigue in breast cancer survivors: results from WF-97415. Support Care Cancer. 2024;32(8):528. doi:10.1007/s00520-024-08717-7